Furthermore, some GLP-1 RAs are reported to reduce the risk of 3-point major adverse cardiovascular events (MACE) 6, 7 , and a meta-analysis of four large-scale clinical studies that assessed GLP-1 RAs concluded that these agents can reduce the risk of cardiovascular events and all-cause mortality 8
Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ongecha JM
A major concern people have when starting GLP-1 medications is that most of the weight lost will be muscle mass
Clinical evidence suggests that there are good results when it comes to treating patients with these drugs
Mounjaro may suit you better if you need a medication that is already available, have type 2 diabetes, or prefer a treatment with a well-established track record